Probiotic supplementation using a mix of three Lactobacillus strains naturally occurring in the human gut microbiota protects against lumbar spine bone loss in healthy, early postmenopausal women, say researchers recently writing in The Lancet Rheumatology.
Apremilast (Otezla, Celgene) resulted in a greater reduction in the number of oral ulcers associated with Behçet’s syndrome than placebo, say researchers recently writing in the New England Journal of Medicine.
A diagnosis of hidradenitis suppurativa may precede the development of ankylosing spondylitis, psoriatic arthritis or rheumatoid arthritis in patients, say researchers writing in the January 22 issue of JAMA Dermatology.
Rheumatoid arthritis patients have an increased risk of developing cardiovascular disease, yet rheumatologists and primary care physicians who treat RA patients sometimes miss the signs and symptoms of CVD in their patients. Learn more in this slideshow.
The placebo response in clinical trials for rheumatoid arthritis appears to have grown over the last two decades with patients exhibiting significant improvements in pain scores with placebo treatment.
In this slideshow, we feature results from some noteworthy rheumatoid arthritis studies that were recently published: improved patient-reported outcomes in refractory rheumatoid arthritis with use of a JAK inhibitor, mortality risk with coronary microvascular dysfunction similar in rheumatoid arthritis and diabetes, prescriber preference affects the length of time a patient takes a conventional synthetic DMARD before switching to a biologic DMARD, and more.
Treatment with the recently approved oral, selective JAK-1 inhibitor upadacitinib (Rinvoq, AbbVie) resulted in significant improvements in various patient-reported outcomes among individuals with rheumatoid arthritis who have had inadequate responses to biologic DMARDs, researchers report in Arthritis Research & Therapy.
Patients and doctors still haven't fully invested in the use of biosimilars, despite a steady rise in the cost of biologics, shows a new report by Harvard researchers.
In a review published last month in Autoimmunity Reviews, British researchers outline factors physicians should consider when contemplating tapering biologic therapies in patients with inflammatory arthritis. How best to wean patients from biologic therapy is an issue that comes up more frequently these days as patients increasingly achieve remission or low disease activity. In this slideshow, we highlight considerations physicians may want to consider in treating these patients.
A 62-year-old woman complained to her doctor about joint pain in her fingers. The joints in her fingers were warm, tender, and slightly swollen. Can you diagnose this patient?